Summit reports two‑year survival data for Western patients, though context lacking on July 23, 2026 Approved EGFR-mutated HARMONi trial Ivonescimab Non-Small Cell Lung Carcinoma Overall Publication Type survival hazard ratio two-year survival data United States Food and Drug Administration Western patients +